Vnitr Lek 2026, 72(6):360-363 | DOI: 10.36290/vnl.2026.068

SGLT2 inhibitors in cardiology, nephrology, and diabetes care: who should take them, how to start treatment, and when to discontinue

Jan Škrha
3. interní klinika 1. LF UK a VFN, Praha

SGLT2 inhibitors, also known as gliflozins, were originally developed as oral antidiabetic agents with mild diuretic and glycosuric effects; they have gradually become a cornerstone of treatment for heart failure and chronic kidney disease, regardless of the presence of diabetes. This article aims to summarize the current status of SGLT2i across internal medicine specialties, define the optimal patient for their use, and provide practical guidance for their safe management, with particular emphasis on perioperative care.

Keywords: SGLT2 inhibitors, gliflozins, heart failure, chronic kidney disease, euglycemic ketoacidosis.

Accepted: September 15, 2026; Published: October 2, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha J. SGLT2 inhibitors in cardiology, nephrology, and diabetes care: who should take them, how to start treatment, and when to discontinue. Vnitr Lek. 2026;72(6):360-363. doi: 10.36290/vnl.2026.068.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. Go to original source...
    2. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. Go to original source...
    3. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. Go to original source... Go to PubMed...
    4. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. Go to original source... Go to PubMed...
    5. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. Go to original source... Go to PubMed...
    6. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. Go to original source...
    7. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127. Go to original source... Go to PubMed...
    8. Šoupal J, Doležalová B, Flekač M, et al. Doporučení pro mezioborovou spolupráci při zahájení léčby SGLT-2 inhibitory z jiné než diabetologické indikace. 2023. [Internet]. Available from: .
    9. Thiruvenkatarajan V, Meyer EJ, Nanjappa N, et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019;123(1):27-36. Go to original source...
    10. Fitridge R, Chuter V, Mills J, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer. Journal of Vascular Surgery. 2023;78(5):1101-1131. Go to original source... Go to PubMed...
    11. Tallarico RT, Jing B, Lu K, et al. Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users. JAMA Surg. 2025;160(6):681-689. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.